NetworkNewsBreaks – Intelligent Bio Solutions In
Post# of 113

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company delivering rapid, non-invasive testing solutions, reported a 20% sequential revenue increase to $728,867 in fiscal Q3 2025, driven by growth in cartridge sales, which now account for 58% of total revenue and strengthen its recurring revenue model. Gross profit surged 91% year-over-year to $341,368, while net loss narrowed by $434,141 to $2.54 million. INBS added 35 new accounts, bringing its active customer base to over 450, and continued expanding internationally through partnerships and multilingual system upgrades. The company also secured its sixth U.S. patent and advanced regulatory efforts across key global markets.
NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://nnw.fm/INBS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

